Schrödinger, Inc.
SDGRHealthcareNASDAQHealth Information Services · Last scanned Jun 3, 2026
Scan Results
Daily timeframeSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the. At a $1.12B market cap, Schrödinger, Inc. ranks as a small-cap company within healthcare. The company operates in two segments, Software and Drug Discovery.
Market Cap
$1.12B
Beta
1.58
P/E (TTM)
—
P/E (Fwd)
-9.55
EPS (TTM)
$-1.40
EPS (Fwd)
$-1.56
ROE
-30.1%
ROA
-15.0%
Cash
$399.0M
Total Debt
$107.0M
Free CF
-$49.4M
52W Change
-37.0%
Annual Financials
Cash vs Debt
Schrödinger, Inc. holds $399.0M in cash against $107.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$49.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -30.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $181.0M (2022) to $255.9M (2025), reflecting a 41% increase over the period.
With a beta above 1.5, SDGR tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, SDGR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Schrödinger, Inc. and its sector.